Ignite Creation Date:
2025-12-25 @ 5:03 AM
Ignite Modification Date:
2025-12-26 @ 4:05 AM
Study NCT ID:
NCT05493618
Status:
WITHDRAWN
Last Update Posted:
2023-01-27
First Post:
2022-08-05
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.
Sponsor:
Hackensack Meridian Health
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-12
Start Date Type:
ESTIMATED
Primary Completion Date:
2025-11
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-11
Completion Date Type:
ESTIMATED
First Submit Date:
2022-08-05
First Submit QC Date:
None
Study First Post Date:
2022-08-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-01-25
Last Update Post Date:
2023-01-27
Last Update Post Date Type:
ACTUAL